<DOC>
	<DOCNO>NCT02940639</DOCNO>
	<brief_summary>A Real-Life Study Evaluate Efficacy Safety Nivolumab Patients Advanced Renal Cell Carcinoma prior therapy .</brief_summary>
	<brief_title>Real-Life Efficacy Safety Nivolumab Patients With Advanced Renal Cell Carcinoma After Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>â‰¥ 18 year diagnosis advance RCC ( confirm histology cytology ) treatment decision initiate treatment nivolumab first time treatment RCC ( accord label approve Germany ) already take sign informed consent diagnosis cancer advance RCC within past 5 year , ie , cancer RCC require systemic treatment . Patients treat curatively 5 year ago evidence recurrence prostate cancer patient active surveillance include previous treatment nivolumab and/or ipilimumab current active participation interventional clinical trial treatment advance RCC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>